Daniel V. Kalinovsky
16/10, Miklukho Maklaya St
Moscow, MOW 117997, Russian Federation
Moscow, MOW 117997, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
GD2-Targeted Minibody-Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model.
Journal: International journal of molecular sciences
Published: January 19, 2026
Effect of Endocytosis Inhibitors on the Cytotoxicity and Antitumor Activity of Anti-GD2 ADCs.
Journal: Acta naturae
Published: December 08, 2025
Endocytosis Properties of GD2-Specific Antibodies in Tumor Cells.
Journal: Biochemistry. Biokhimiia
Published: May 14, 2025
Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment-Drug Conjugates Carrying Maytansinoids DM1 and DM4.
Journal: Current issues in molecular biology
Published: August 28, 2023
Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells.
Journal: International journal of molecular sciences
Published: November 29, 2022
Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.
Journal: Journal for immunotherapy of cancer
Published: June 01, 2022
RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype.
Journal: Biomedicines
Published: April 27, 2020
Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.
Journal: Journal of immunology research
Published: March 23, 2018
Properties of a cryptic lysyl oxidase from haloarchaeon Haloterrigena turkmenica.
Journal: PeerJ
Published: January 02, 2018
Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations.
Journal: Current medicinal chemistry
Published: March 02, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026